NovoCure (NVCR) Debt to Equity (2016 - 2025)
NovoCure (NVCR) has disclosed Debt to Equity for 11 consecutive years, with $0.57 as the latest value for Q4 2025.
- Quarterly Debt to Equity rose 112.07% to $0.57 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.57 through Dec 2025, up 112.07% year-over-year, with the annual reading at $0.57 for FY2025, 112.07% up from the prior year.
- Debt to Equity hit $0.57 in Q4 2025 for NovoCure, roughly flat from $0.57 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.59 in Q1 2024 to a low of $0.27 in Q2 2024.
- Historically, Debt to Equity has averaged $1.0 across 5 years, with a median of $1.28 in 2022.
- Biggest five-year swings in Debt to Equity: soared 152.77% in 2021 and later crashed 83.02% in 2025.
- Year by year, Debt to Equity stood at $1.37 in 2021, then dropped by 6.41% to $1.28 in 2022, then increased by 12.55% to $1.44 in 2023, then tumbled by 81.27% to $0.27 in 2024, then surged by 112.07% to $0.57 in 2025.
- Business Quant data shows Debt to Equity for NVCR at $0.57 in Q4 2025, $0.57 in Q3 2025, and $0.28 in Q2 2025.